Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: (R)-tofisopam; Artofisopam; R-tofisopam

Latest Information Update: 24 Jun 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Pharmos Corporation
  • Class Antispasmodics; Anxiolytics; Benzodiazepines; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Irritable bowel syndrome

Highest Development Phases

  • Suspended Irritable bowel syndrome

Most Recent Events

  • 28 Oct 2010 Dextofisopam is still available for licensing. www.pharmoscorp.com
  • 14 Sep 2009 Efficacy and adverse events data from a Phase-II trial in Irritable bowel syndrome released by Pharmos Corporation
  • 14 Sep 2009 Pharmos Corporation completes a Phase-IIb trial in Irritable bowel syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top